This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, S. C. Articles by Theodorescu, D. Search for Related Content PubMed PubMed Citation Articles by Smith, S. C. Articles by Theodorescu, D.

The Metastasis-Associated Gene CD24 Is Regulated by Ral GTPase and Is a Mediator of Cell Proliferation and Survival in Human Cancer

Departments of ¹ Molecular Physiology, ² Health Evaluation Sciences, and ³ Pathology and ⁴ Mellon Prostate Cancer Institute, University of Virginia, Charlottesville, Virginia and ⁵ Genomics Institute of the Novartis Research Foundation, San Diego, California

Requests for reprints: Dan Theodorescu, Department of Urology, University of Virginia, P.O. Box 800422, Charlottesville, VA 22908-800422. Phone: 434-924-0042; Fax: 434-982-3652; E-mail: dt9d{at}virginia.edu.

Ral GTPases are important mediators of transformation, tumorigenesis, and cancer progression. We recently identified the metastasis-associated protein CD24, a glycosyl phosphatidyl inositol–linked surface protein, as a downstream target of Ral signaling by profiling the expression of RalA/B–depleted bladder carcinoma cells. Because CD24 is highly expressed in bladder and many other tumor types, we sought to determine if this protein plays an essential role in maintaining the malignant phenotype. Here, we show that loss of CD24 function in cell lines derived from common tumor types is associated with decreased rates of cell proliferation, clonogenicity in soft agar, changes in the actin cytoskeleton, and induction of apoptosis. Given these phenotypes, we evaluated a human bladder cancer tissue microarray by immunohistochemistry for CD24 to determine if CD24 is a prognostic cancer biomarker. Multivariate analysis showed that increased CD24 expression correlated with shorter patient disease-free survival (P = 0.07). In conclusion, we show that CD24 is a novel and functionally relevant Ral-regulated target and a potentially important prognostic marker. We suggest that these insights may lead to future therapeutic approaches that seek to eliminate CD24 function in cancer cells. (Cancer Res 2006; 66(4): 1917-22)

This article has been cited by other articles:

				E. Sagiv, A. Starr, U. Rozovski, R. Khosravi, P. Altevogt, T. Wang, and N. Arber Targeting CD24 for Treatment of Colorectal and Pancreatic Cancer by Monoclonal Antibodies or Small Interfering RNA Cancer Res., April 15, 2008; 68(8): 2803 - 2812. [Abstract] [Full Text] [PDF]

				Y.-Y. Chou, Y.-M. Jeng, T.-T. Lee, F.-C. Hu, H.-L. Kao, W.-C. Lin, P.-L. Lai, R.-H. Hu, and R.-H. Yuan Cytoplasmic CD24 Expression Is a Novel Prognostic Factor in Diffuse-Type Gastric Adenocarcinoma Ann. Surg. Oncol., October 1, 2007; 14(10): 2748 - 2758. [Abstract] [Full Text] [PDF]

				S. C. Smith, G. Oxford, A. S. Baras, C. Owens, D. Havaleshko, D. L. Brautigan, M. K. Safo, and D. Theodorescu Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer Clin. Cancer Res., July 1, 2007; 13(13): 3803 - 3813. [Abstract] [Full Text] [PDF]

				T. Fukushima, T. Tezuka, T. Shimomura, S. Nakano, and H. Kataoka Silencing of Insulin-like Growth Factor-binding Protein-2 in Human Glioblastoma Cells Reduces Both Invasiveness and Expression of Progression-associated Gene CD24 J. Biol. Chem., June 22, 2007; 282(25): 18634 - 18644. [Abstract] [Full Text] [PDF]